SCHEMBL5694071

SCHEMBL5694071

Nc1nc2[nH]cnc2c(=O)n1C(=O)COc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
GAA P10253 3/20 0.41
L3MBTL1 Q9Y468 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
HTT P42858 1/20 0.38
CPT2 P23786 1/20 0.37
CPT1A P50416 1/20 0.37
ALOX15 P16050 1/20 0.37
KDM4E B2RXH2 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
USP2 O75604 1/20 0.36
POLB P06746 1/20 0.36
NPC1 O15118 1/20 0.36
ALDH1A1 P00352 1/20 0.36
TP53 P04637 1/20 0.36
ALOX12 P18054 1/20 0.36
RAB9A P51151 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
ADORA2A P29274 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3072977 0.83 MGMT (0.32) GAAKDM4EADORA2A
SCHEMBL5694108 0.81 MEN1 (0.41) KMT2AMEN1GAAL3MBTL1ALOX15
SCHEMBL5694185 0.79 NPC1 (0.51) KMT2AMEN1GAASMN1; SMN2KDM4E
SCHEMBL8583444 0.78 KMT2A (0.42) KMT2AMEN1GAAL3MBTL1KDM4E
SCHEMBL8843867 0.77 PDE4A (0.38) KMT2AADORA3ADORA2A
SCHEMBL1740456 0.76 ALDH1A1 (0.36) KMT2AMEN1GAASMN1; SMN2KDM4E
SCHEMBL6821768 0.76 GDA (0.39) KMT2AMEN1KDM4ETDP1POLB
SCHEMBL218666 0.74 GDA (0.34) ADORA3ADORA2AALPL
Bromide SCHEMBL8165610 0.73 GDA (0.33)
SCHEMBL5347861 0.73 XDH (0.42) ADORA3ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3004131-B1 PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES AM CHEMICALS LLC (US) 2020-07-22 EP claimed
EP-3004131-A1 PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES AM Chemicals Llc (US) 2016-04-13 EP claimed
US-20160083414-A1 PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES AM CHEMICALS LLC (US) 2016-03-24 US claimed
WO-2014197714-A1 PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES AM CHEMICALS LLC (US) 2014-12-11 WO claimed
EP-3004131-B1 PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES AM CHEMICALS LLC (US) 2020-07-22 EP disclosed
US-10669301-B2 Phosphoramidite building blocks for sugar-conjugated oligonucleotides AM CHEMICALS LLC (US) 2020-06-02 US disclosed
US-20180362572-A1 PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES AM CHEMICALS LLC (US) 2018-12-20 US disclosed
US-10087208-B2 Phosphoramidite building blocks for sugar-conjugated oligonucleotides AM CHEMICALS LLC (US) 2018-10-02 US disclosed
EP-3004131-A1 PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES AM Chemicals Llc (US) 2016-04-13 EP disclosed
US-20160083414-A1 PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES AM CHEMICALS LLC (US) 2016-03-24 US disclosed
WO-2014197714-A1 PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES AM CHEMICALS LLC (US) 2014-12-11 WO disclosed
US-20140038181-A1 CHEMICALLY SUBSTITUTED THERMOSENSITIVE PROBES AND COFACTORS FOR HOT START LIGATION TRILINK BIOTECHNOLOGIES, INC. 2014-02-06 US disclosed
WO-2012094343-A1 CHEMICALLY SUBSTITUTED THERMOSENSITIVE PROBES AND COFACTORS FOR HOT START LIGATION TRILINK BIOTECHNOLOGIES (US) 2012-07-12 WO disclosed
US-20060167241-A1 Method for synthesizing cyclic bisdinucleoside MITSUI CHEMICALS, INC. (JP) 2006-07-27 US disclosed
EP-1645561-A1 METHOD OF SYNTHESIZING CYCLIC BISDINUCLEOSIDE Mitsui Chemicals, Inc. (JP) 2006-04-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10669301-B2 Phosphoramidite building blocks for sugar-conjugated oligonucleotides DERA, FBP1, PNKP KMT2A 2198/4885MEN1 724/4885GAA 597/4885
US-20180362572-A1 PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES DERA, TYMP, PAICS KMT2A 2408/4885MEN1 873/4885GAA 593/4885
US-10087208-B2 Phosphoramidite building blocks for sugar-conjugated oligonucleotides DERA, TYMP, PAICS KMT2A 2408/4885MEN1 873/4885GAA 593/4885
US-20060167241-A1 Method for synthesizing cyclic bisdinucleoside NSUN2, POLR2H, POLB KMT2A 1088/4885MEN1 467/4885GAA 3189/4885
US-20160083414-A1 PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES DERA, TYMP, PAICS KMT2A 2408/4885MEN1 873/4885GAA 593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.